BMTI BioMimetic Therapeutics, Inc is oversold. Looking for a nice bounce. FDA panel voted favorably for Augment. Price target is $35 + as BMTI moves closer towards FDA approval. Possible buyout / takeover candidate, imo.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.